Can pelvic lymphadenectomy be omitted in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer? by unknown
Wang et al. SpringerPlus  (2016) 5:1262 
DOI 10.1186/s40064-016-2927-5
RESEARCH
Can pelvic lymphadenectomy be 
omitted in patients with stage IA2, IB1, and IIA1 
squamous cell cervical cancer?
Yaxian Wang1,2†, Tingting Yao1†, Jin Yu1, Jing Li1, Qionghua Chen2 and Zhongqiu Lin1*
Abstract 
Purpose: This study aimed to identify the surgical-pathologic risk factors of lymph node metastasis (LNM) in 
patients with early stage squamous cell cervical cancer and to evaluate the potential efficacy of omitting pelvic 
lymphadenectomy.
Methods: A total of 276 patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer receiving primary radical 
hysterectomy with pelvic lymphadenectomy were included in this study.
Results: The incidences of LNM in patients with stage IA2, IB1, and IIA1 squamous cell cervical cancer were 0 % (0/8), 
17.4 % (36/207), and 29.5 % (18/61), respectively. The most common location of LNM was the obturator lymph node. 
Human papilloma virus 16 subtype was the most common infection in early stage squamous cell cervical cancer. Uni-
variate analysis revealed that squamous cell carcinoma antigen (SCCAg) greater than 1.5 μg/L (p < 0.001), tumor size 
greater than 2 cm (p < 0.001), tumor size greater than 3 cm (p < 0.001), depth of stromal invasion (p < 0.001) and lym-
phovascular invasion (p < 0.001) were associated with LNM. Logistic regression analysis revealed that depth of stromal 
invasion {model 1 [p = 0.006; odds ratio (OR) 2.161; 95 % confidence interval (CI) 1.251–3.734], model 2 [p = 0.002; 
OR 2.344; 95 % CI 1.337–3.989]}, lymphovascular invasion [model 1 (p = 0.004; OR 2.967; 95 % CI 1.411–6.237), model 
2 (p = 0.004; OR 2.978; 95 % CI 1.421–6.243)], and SCCAg greater than 1.5 μg/L [model 1 (p = 0.023; OR 2.431; 95 % CI 
1.129–5.235), model 2 (p = 0.024; OR 2.418; 95 % CI 1.125–5.194)] were independently associated with LNM.
Conclusions: Pelvic lymphadenectomy may be omitted in patients with SCCAg lower than 1.5 μg/L, superficial stro-
mal invasion and without lymphovascular invasion in stage IA2, IB1, IIA1 squamous cell cervical cancer.
Keywords: Early stage cervical cancer, Squamous cell carcinoma antigen, Pelvic lymphadenectomy, Lymph node 
metastasis, Stromal invasion, Lymphovascular invasion
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Background
Cervical cancer is a global public health problem and a sig-
nificant cause of death among women in developing coun-
tries (Forouzanfar et al. 2011). The International Federation 
of Gynecology and Obstetrics (FIGO) recommends a clini-
cal staging system for cervical cancer. Although lymph 
node status assessment does not change clinical stage, 
lymph node metastasis (LNM) is an independent factor in 
poor survival and relapse of cervical cancer (Pieterse et al. 
2007; Ditto et al. 2013; Bai et al. 2015). Guidelines recom-
mend radical hysterectomy with pelvic lymphadenectomy 
is the preferred treatment for early stage (FIGO IA2, IB1, 
IIA1) cervical cancer. However, pelvic lymphadenectomy is 
associated with potential risk of serious postoperative com-
plication, such as nerve or vascular injury, lymphedema 
lymphedema in the lower limbs and pelvic lymph cysts 
with concomitant infection (Matsuura et al. 2006; Achouri 
et al. 2013; Kawamura et al. 2015).
One research suggest that the number of removed lymph 
nodes in pelvic lymphadenectomy pay no effect on the 
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prognosis of patients with early stage cervical cancer with 
negative pelvic lymph nodes (Pieterse et al. 2007). Approx-
imately 80  % of cervical cancer cases are squamous cell 
carcinomas. Non-squamous histology has been shown to 
be an independent prognostic factor for disease-free and 
overall survival compared with squamous cell carcinoma 
in cervical cancer with LNM (Kodama et  al. 2006; Park 
et al. 2010). Thus, we speculate that pelvic lymphadenec-
tomy may be avoided in patients with early cervical squa-
mous cell cancer who are in low risk of LNM, to reduce 
associated morbidity of complete lymphadenectomy and 
long-term effects of postoperative complication, may help 
to improve the postoperative quality-of-life of patients.
Squamous cell carcinoma antigen (SCCAg) is the 
serum tumor marker most commonly used for clinical 
monitoring of cervical squamous cell cancer(Kim 2013). 
Elevated pre-treatment SCCAg levels correlate with 
LNM and a poor prognosis in cervical squamous cell 
cancer (van de Lande et al. 2009; Kawaguchi et al. 2013).
In the present study, we retrospectively reviewed the 
records of patients with stage IA2, IB1, and IIA1 cervical 
squamous cell cancer who received radical hysterectomy 
with pelvic lymphadenectomy. We examined the effect of 
clinicopathologic factors, also take preoperative serum 
SCCAg into account, on the risk for LNM to identify 




We retrospectively analyzed the data of patients with cer-
vical cancer treated at the Department of Gynecological 
Oncology, Sun Yat-sen Memorial Hospital of Sun Yat-sen 
University between January 2012 and June 2015. This 
study included patients who met the following criteria: 
(1) FIGO IA2, IB1, or IIA1 cervical cancer and received 
radical hysterectomy with pelvic lymphadenectomy; (2) 
histological confirmed squamous cell carcinoma accord-
ing to FIGO classification system; (3) no preoperative 
radiotherapy or chemotherapy. The study was performed 
in accordance with the Declaration of Helsinki and was 
approved by the ethics committee of the Sun Yat-sen 
Memorial Hospital of Sun Yat-sen University. All patients 
provided written consent for storage of their information 
in the hospital database and for use of this information in 
our research.
Surgical procedures
Radical hysterectomy included complete removal of the 
uterus, ovaries, Fallopian tubes, cervix, upper vagina and 
parametrium. A systematic lymphadenectomy consisted 
of dissections of lymph nodes in the common iliac, exter-
nal iliac, internal iliac, obturator and deep inguinal areas, 
at both sides. The cranial, caudal, ventral, dorsal, lateral 
and medial boundaries of the lymphadenectomy were 
3  cm above the bifurcation of the internal and external 
iliac arteries, the level of deep iliac circumflex vein, the 
level of peritoneum, the level of the obturator nerve, the 
inside of the psoas major muscle and the lateral border 
of ureter, respectively. Para-aortic lymphadenectomy was 
performed only in case of gross metastasis to the com-
mon iliac nodes or para-aortic nodes was suspected.
SCCAg assay
Serum samples were taken routinely at the patient’s initial 
visit before surgery for SCCAg analysis. Serum SCCAg 
levels were analyzed using an automated chemilumi-
nescence immunoassay (CLIA) system (i2000, Abbott, 
USA) according to the manufacturer’s instructions. The 
recommended cutoff level of 1.5 ng/ml was applied. Ten 
patients had no serum SCCAg data.
Sample collection and HPV testing
The gynecologist rotated the disposable cervical cell col-
lection brush clockwise 3–5 times at the cervical junc-
tion to collect exfoliated cervical cells. The cervical brush 
was removed, stored in preservation solution, and sent 
to laboratory to test immediately. HPV genotypes were 
detected using nucleic acid molecule flow-through PCR 
and membrane hybridization using gene chip technol-
ogy with the 21HPV Genoarray Diagnostic Kit (Hybribio 
Inc, Guangzhou, China). HPV nucleic acid was extracted, 
and gene amplification and molecular hybridization were 
performed, according to the manufacturer’s instructions. 
There were 21 HPV subtypes tested simultaneously in a 
membrane including 13 types of high-risk HPVs (HPV-
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), 5 low-
risk HPVs (HPV-6, 11, 42, 43,and 44) and 3 HPVs that are 
common in Chinese people (HPV-53, 66, and CP8304). 
Twenty-four patients had no HPV testing data.
Statistical analysis
The relationship between clinical and pathological factors 
and LNM was examined by univariate analysis using the 
χ2 and Fisher’s exact probability tests. The independent 
effects of clinical and pathological factors on LNM were 
then determined by logistic regression analysis, in which 
factors that were statistically significant in univariate 
analysis. A p value <0.05 was considered significant for all 
analyses. SPSS software (version 16.0; IBM Corporation, 
Armonk, NY, USA) was used for statistical analysis.
Results
Clinicopathologic characteristics of patients
A total of 276 patients treated for squamous cell cervical 
cancer between January 2012 and June 2015 met criteria 
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for inclusion in the present study. Table  1 summarizes 
the clinicopatholgic characteristics of the 276 patients 
who had early stage cervical squamous cell cancer with a 
median age of 49 years (range 22–80 years). One hundred 
and fifty-eight patients (57.2 %) were premenopausal and 
118 patients (42.8 %) were postmenopausal. Staging indi-
cated that 8 patients (2.9 %) had FIGO IA2, 207 patients 
(75.0  %) had FIGO IB1, and 61 patients (22.1  %) had 
FIGO IIA1. Two hundred and thirty-two patients (92 %) 
had positive HPV infection and 68 patients (25.6  %) 
with SCCAg greater than 1.5 μg/L. Analysis of histologi-
cal grade indicated that 98.5  % patients (272/276) had 
moderately to poorly differentiated cancer. Seventy-nine 
patients (28.6  %) had deep-full thickness stromal inva-
sion, and 129 patients (46.7  %) with lymphovascular 
invasion.
HPV infection
A total of 252 patients had HPV testing data. Two hun-
dred and thirty-two patients (92.1  %) had positive HPV 
infection. There were 12 HPV subtypes (HPV-16, 18, 31, 
33, 39, 51, 52, 56, 58, 66 and CP8304) as detected. Single 
HPV subtype infections accounted for 81.0  % (188/232) 
of the total number of infections, and multiple-sub-
type infections accounted for 19.0  % (44/232), includ-
ing 14.2  % (33/232) of patients with a double infection, 
Table 1 Clinicopathological characteristics of  patient with  stage IA2/IB1/IIA1 cervical squamous cell cancer (n =  276) 
in relation to the pelvic lymph node status
Characteristics Total Positive lymph node metastasis n (%) Negative lymph node metastasis n (%) p-value
54 222
Age, years
 <40 45 8 (14.8) 37 (16.7) 0.947
 ≥40 231 46 (85.2) 185 (83.3)
Menopausal status
 Premenopausal 158 26 (48.1) 132 (59.5) 0.321
 Postmenopausal 118 28 (51.9) 90 (40.5)
FIGO stage
 IA2/IB1 215 36 (66.7) 179 (80.7) 0.085
 IIA1 61 18 (33.3) 43 (19.4)
HPV infection status
 Negative 20 1 (2.0) 19 (9.5) 0.180
 Positive 232 50 (98.0) 182 (90.5)
SCCAg (μg/L)
 ≤1.5 198 24 (46.1) 174 (81.3) <0.001
 >1.5 68 28 (53.9) 40 (18.7)
Histological grade
 Well differentiated 4 0 (0) 4 (1.8) 0.733
 Moderately differentiated 163 34 (63.0) 129 (58.1)
 Poorly differentiated 109 20 (37.0) 89 (40.1)
Tumor size (cm)
 ≤2 124 8 (14.8) 116 (52.3) <0.001
 >2 152 46 (85.2) 106 (47.7)
Tumor size(cm)
 ≤3 225 32 (59.3) 193 (86.9) <0.001
 >3 51 22 (40.7) 29 (13.1)
Depth of stromal invasion
 Superficial 129 6 (11.1) 122 (55.0) <0.001
 Middle 69 16 (29.6) 53 (23.9)
 Deep-full 79 32 (59.3) 47 (21.1)
Lymphovascular invasion
 Negative 147 14 (25.9) 133 (59.9) <0.001
 Positive 129 40 (74.1) 89 (40.1)
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4.7 % (11/232) of patients with a triple or more infection. 
The HPV16 subtype was the most common infection 
(n =  190, 81.9  %), followed by HPV58 (n =  19, 8.3  %), 
HPV52 (n = 18, 7.9 %), HPV18 (n = 16, 7.1 %), HPV 39 
(n = 11, 4.7 %).
Lymph node metastasis
The patterns of lymph node metastasis are summa-
rized in Table 2. The median number of dissected lymph 
nodes was 23 (range 10–52) (in Fig. 1). Fifty-four patients 
(19.6  %) had 99 positive lymph node metastasis. The 
incidences of LNM in patients with stage IA2, IB1, and 
IIA1 were 0 % (0/8), 17.4 % (36/207), and 29.5 % (18/61), 
respectively. Multiple (≥2) LNM was found in 10.9  % 
(30/276). Bilateral LNM was found in 4.7  % (13/276). 
Skip LNM was found in 1.1  % (3/276). The obturator 
lymph node was the most common location of lymph 
node metastasis (n = 50, 50.5 %), followed by the inter-
nal iliac lymph node (n  =  16, 16.2  %), common iliac 
lymph node (n = 14, 14.1 %), external iliac lymph node 
(n = 11, 11.1 %), parametrial lymph node (n = 4, 4.0 %), 
inguinal lymph node(n = 3, 3.0 %) and para-aortic lymph 
node(n = 1, 1.0 %).
Univariate analysis of risk factors with LNM
Table  1 shows the results of univariate analysis of the 
correlation between clinicopathologic factors and LNM. 
Patients with SCCAg greater than 1.5  μg/L (p  <  0.001), 
tumor size greater than 2  cm (p  <  0.001), tumor size 
greater than 3 cm (p < 0.001), depth of stromal invasion 
(p < 0.001) and lymphovascular invasion (p < 0.001) were 
significantly associated with LNM. Age, menopausal sta-
tus, FIGO stage, HPV infection status and histological 
grade were not associated with LNM (p > 0.05).
Multivariate analysis of risk factors with LNM
Table  3 shows multivariate analysis of the clinicopatho-
logical factors associated with the LNM in which factors 
that were statistically significant in univariate analysis 
using 2 models. The results showed that depth of stro-
mal invasion {model 1 [p = 0.006; odds ratio (OR) 2.161; 
95  % confidence interval (CI) 1.251–3.734], model 2 
[p  =  0.002; OR 2.344; 95  % CI 1.337–3.989]}, lympho-
vascular invasion [model 1 (p =  0.004; OR 2.967; 95  % 
CI 1.411–6.237), model 2 (p = 0.004; OR 2.978; 95 % CI 
1.421–6.243)], and SCCAg greater than 1.5 μg/L [model 
1 (p =  0.023; OR 2.431; 95  % CI 1.129–5.235), model 2 
(p  =  0.024; OR 2.418; 95  % CI 1.125–5.194)] were sig-
nificantly and independently associated with LNM. 
Tumor size were not significantly associated with LNM 
(p > 0.05).
Discussion
In the present study, the incidences of LNM in patients 
with stage IA2, IB1, and IIA1 cervical squamous cell can-
cer were 0 % (0/8), 17.4 % (36/207), and 29.5 % (18/61), 
Table 2 Location of  pelvic lymph node metastasis in  54 
patients (99 positive lymph nodes) with stage IA2/IB1/IIA1 
cervical squamous cell cancer
Pelvic lymph node location Metastasis (%)
Para-aortic 1.0 (1/99)
Common iliac 14.2 (14/99)
External iliac 11.1 (11/99)




Fig. 1 Number of removed lymph nodes per case: 1–276 women. 
X-axis: disease groups. Y-axis: number of removed lymph nodes. Bar 
mean
Table 3 Logistic regression analysis of  the clinicopatho-
logical variables associated with  the pelvic lymph node 
status using 2 models
Variables OR 95 % CI p
Model 1
 Depth of stromal invasion 2.161 1.251–3.734 0.006
 Lymphovascular invasion 2.967 1.411–6.237 0.004
 SCCAg (>μg/L) 2.431 1.129–5.235 0.023
 Tumor size (>2 cm) 2.277 0.909–5.706 0.079
Model 2
 Depth of stromal invasion 2.344 1.337–3.989 0.002
 Lymphovascular invasion 2.978 1.421–6.243 0.004
 SCCAg (>μg/L) 2.418 1.125–5.194 0.024
 Tumor size (>3 cm) 1.761 0.797–3.890 0.162
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respectively. The result is similar to the previous studies 
that LNM in cervical cancer was found in 0–20.3  % of 
patients with stage IA2-IB1 and in 16–38.6 % of patients 
with stage IIA1 (Hongladaromp et al. 2014; Togami et al. 
2014; Liu et al. 2015; Zhou et al. 2015). In patients with-
out LNM, the number of removed lymph nodes in pel-
vic lymphadenectomy was not associated with 5-year 
disease-free survival (Suprasert et  al. 2012). But there 
are some long-term postoperative complication of pel-
vic lymphadenectomy, the overall incidence of sympto-
matic postoperative lymphocysts was 34.5  % (Achouri 
et al. 2013), and the incidence of lower-limb lymphedema 
increased over time, 12.9 % at 1 year, 20.3 % at 5 years, 
and 25.4  % at 10  years (Hareyama et  al. 2015), both of 
which significantly harmed the quality-of-life. However, 
compared to undergoing open surgery, pelvic lymphad-
enectomy had a less impact on patients undergoing lapa-
roscopic surgery, less blood loss, a lower transfusion rate, 
less lymphocele infection and other complications (Xiao 
and Zhang 2015; Bogani et  al. 2014). Nevertheless, it 
means more than 60 % of patients in early stage cervical 
cancer without LNM will derive no benefit from pelvic 
lymphadenectomy and that it may be safely avoided in 
such patients. It is important to identify factors associ-
ated with the risk of LNM to reduce unnecessary pelvic 
lymphadenectomy.
Results of our multivariate analysis suggested that in 
276 patients with stage IA2, IB1, and IIA1 cervical squa-
mous cell cancer who received radical hysterectomy with 
pelvic lymphadenectomy, SCCAg greater than 1.5  μg/L, 
deep-full thickness stromal invasion and lymphovascu-
lar invasion were significant and independent factors for 
LNM, while tumor size were not significantly associated 
with LNM (p > 0.05).
Several studies found that lymphovascular inva-
sion, and deep stromal invasion were statistically inde-
pendently associated with LNM in early stage cervical 
cancer (Bai et al. 2015; Li et al. 2015; Zhou et al. 2015). 
One research demonstrated that patients with cervical 
cancer and found that stage IIA and advanced histolog-
ical grade increased the risk for LNM (Li et  al. 2012). 
Another also studied patients with stage IA–IIB squa-
mous cell cervical cancer and found lymphovascular 
invasion, parametrial invasion, and depth of stromal 
invasion were identified as independent clinicopatho-
logical risk factors for LNM (Liu et  al. 2015). But they 
did not analysis the SCCAg data. It had been found that 
SCCAg greater than 1.65  μg/L can predict LNM more 
accurately in stage IB1 (76  %) than in stage IIA (53  %) 
(van de Lande et al. 2009). In our study, SCCAg greater 
than 1.5  μg/L was significant and independent factors 
for LNM in stage IA2, IB1, and IIA1 squamous cell cer-
vical cancer.
One prior study by Togami investigated patients with 
stage IA2-IIB cervical cancer and found that parame-
trial involvement and primary tumor size greater than 
2 cm increased the risk of LNM (Togami et al. 2014). A 
survey by the Japan Clinical Oncology Group found that 
in patients with stage IB1 with clinical tumor diameter 
≤2  cm, which available by magnetic resonance imaging 
(MRI) or specimens by cone biopsy, had less LNM and 
more favorable 5-year overall survival (Kato et al. 2015).
As MRI is a more accurate noninvasive modality for pre-
operative evaluation of tumor size compared with pelvic 
examination (Zhang et al. 2014), in our study, tumor size 
which was evaluated by pelvic examination was not an 
independent factor for LNM.
Sentinel lymph node (SLN) mapping and biopsy 
has already been used in cervical cancer. A systematic 
review reported that SLN biopsy has the highest detec-
tion rate when 99  mTc is used in combination with 
blue dye (97 %), and a sensitivity of 92 % (van de Lande 
et  al. 2007). However, the detection of sentinel lymph 
nodes requires an injection of technetium or blue dye 
and frozen section analysis. The sensitivities of SLN in 
diagnosing micrometastases were 81  % and the false 
negative rate of intra-operative frozen section examina-
tion was up to 44  % (Slama et  al. 2013), while another 
study from Canada reported that intra-operative frozen 
examination of SLN accurately predicts the status of 
pelvic lymph nodes. The sensitivity for the detection of 
macro and micrometastatic disease was 88.9 % and neg-
ative predictive value was 98.8 % (Martínez et al. 2013). 
Recently, Indocyanine green (ICG), has been introduced 
in SLN mapping. A meta-analysis found that ICG SLN 
mapping had higher overall and bilateral detection rates 
while compared with blue dyes, and there was no dif-
ference while compared with combination of blue dyes 
and 99mTc (Ruscito et  al. 2016). A study from Italy 
also found that in women with early stage cervical can-
cer, bilateral mapping was achieved in 98.5  % for ICG 
and 76.3 % for Tc-99m with blue dye (Buda et al. 2016). 
Undergoing laparoscopic surgery, ICG SLN mapping in 
cervical cancer also provided high overall and bilateral 
detection rates (Imboden et  al. 2015). However, com-
pared to patients with uterus in  situ, SLN mapping in 
occult cervical cancer patients has lower detection rates, 
these patients needed proper management (Papadia 
et  al. 2016). A diagnostic review found that early stage 
cervical cancer patients (FIGO IA2, IB1, IIA1) who had 
bilateral negative SLN result had a residual risk of 0.08 % 
(1/1257) on occult metastases, recommended not to 
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perform a full pelvic lymphadenectomy in these patients 
(Tax et  al. 2015). Further research should be made in 
order to standardize this method and confirm whether 
SLN biopsy can be used to replace pelvic lymphadenec-
tomy for patients with early stage cervical cancer.
The retrospective nature of this study is its major limi-
tation. Moreover, it was a single-center study and the 
sample was small, so our patients should not be consid-
ered representative of the general population. However, 
although SCC-Ag was one preoperative clinicopatho-
logic factor in the prediction of LNM, depth of stromal 
invasion and lymphovascular invasion was evaluated 
after conization but mainly on the basis of postoperative 
factors.
Conclusions
In conclusion, depth of stromal invasion, lymphovascular 
invasion and SCCAg greater than 1.5 μg/L were risk fac-
tors with LNM in patients with stage IA2, IB1, and IIA1 
squamous cell cervical cancer. We propose pelvic lym-
phadenectomy maybe ommitted in patients with super-
ficial stromal invasion, SCCAg lower than 1.5  μg/L and 
without lymphovascular invasion and thereby reduce the 
incidence of postoperative complications. More studies 
are needed to confirm our findings.
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